Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

See Locations Near You

Summary

The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients.

Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must have a history of breast cancer.
Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management.
Patient must be willing to undergo a duct lavage.
Patient must sign an Informed Consent.

Exclusion Criteria:

None.

Study is for people with:

Breast Cancer

Estimated Enrollment:

42

Study ID:

NCT01207635

Recruitment Status:

Completed

Sponsor:

M.D. Anderson Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

UT MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

42

Study ID:

NCT01207635

Recruitment Status:

Completed

Sponsor:


M.D. Anderson Cancer Center

How clear is this clinincal trial information?

Clinical Trial Resources

SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials for Breast Cancer
Have You Been Diagnosed With Late-Stage Breast Cancer? Know That You Have Treatment Options.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider